MorphoSys marches ahead with plans to file myelofibrosis drug despite mixed PhIII results
MorphoSys is declaring success on a Phase III study involving the key cancer drug from its $1.7 billion buyout of Constellation, but a secondary endpoint miss appears to be causing concern.
The MANIFEST-2 trial tested MorphoSys’ BET inhibitor, pelabresib, in combination with Incyte’s ruxolitinib (sold, among other names, as Jakafi), as a treatment for a rare blood cancer called myelofibrosis. The combo met the primary endpoint, demonstrating a statistically significant improvement in the proportion of patients achieving at least a 35% reduction in spleen volume — a metric also known as SVR35 — at week 24.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.